Advertisement

131I-MIBG Therapy in metastatic phaeochromocytoma and paraganglioma

  • Gonca Kara GedikEmail author
  • Cornelis A. Hoefnagel
  • Evert Bais
  • Renato A. Valdés Olmos
Original article

Abstract

Purpose

131Iodine metaiodobenzylguanidine (131I-MIBG) is a radiopharmaceutical used for scintigraphic localisation of phaeochromocytomas and paragangliomas. The experience with its therapeutic use is limited. We report our experience for the treatment of malignant phaeochromocytoma and paraganglioma.

Materials and methods

The charts of 19 patients with malignant phaeochromocytoma (n = 12) or paraganglioma (n = 7), who were treated with 131I-MIBG, were retrospectively reviewed. Four patients (21%) received radiotherapy, three (16%) chemotherapy, and in one patient (5%), both chemotherapy and radiotherapy was given before 131I-MIBG therapy. Response to 131I-MIBG treatment was evaluated by objective as tumour response, biochemical and subjective response.

Results

Of the 19 patients, 13 (68%) were men, 6 (32%) were women. Ages ranged from 22 to 68 years (median, 47). The median initial dose was 7.4 GBq (200 mCi; range, 6.7 GBq-25.9 GBq, 180-700 mCi); median cumulative dose was 22.2 GBq (600 mCi; range, 6.8 GBq-81.4 GBq, 183-2200 mCi). Objective tumour response was achieved in 47% of the patients. Biochemical response rate was 67%, and symptomatic response was seen in 89% of the patients. Overall median follow-up was 29 months, with a range of 3-93 months. Haematologic complications were the most common side effects and were observed in 26% of the patients.

Conclusion

Our data support that symptomatic and biochemical response can be reached with 131I-MIBG therapy in patients with metastatic phaeochromocytoma and paraganglioma. Although complete tumour response was not observed, the palliation and control of tumour function by 131I-MIBG therapy may be valuable for the patients.

Keywords

131I-MIBG Phaeochromocytoma Paraganglioma Malignant Radionuclide therapy 

References

  1. 1.
    Yeo H, Roman S. Pheochromocytoma and functional paraganglioma. Curr Opin Oncol 2005;17:13-8.CrossRefPubMedGoogle Scholar
  2. 2.
    Chan FK, Choi KL, Tiu SC, Shek CC, Yong TK, Au Yong TK. A case of giant malignant phaeochromocytoma. Hong Kong Med J 2000;6:325-8.PubMedGoogle Scholar
  3. 3.
    Averbuch SD, Steakley CS, Young RC, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine. Ann Intern Med 1988;109:267-73.CrossRefPubMedGoogle Scholar
  4. 4.
    Hoefnagel CA. Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumors. Eur J Nucl Med 1994;21:561-81.PubMedGoogle Scholar
  5. 5.
    Van der Harst E, de Herder WW, Bruining HA, Bonjer HJ, de Krijger RR, Lamberts SW, et al. 123I Metaiodobenzylguanidine and 111In Octreotide uptake in benign and malignant pheochromocytomas. Clin Endocrinol Metab 2001;86:685-93.Google Scholar
  6. 6.
    Ackery DM, Troncone L. Session on the role of [131I]metaiodobenzylguanidine in the treatment of malignant phaeochromocytoma. Chairmen’s report. J Nucl Biol Med 1991;34:318-20.Google Scholar
  7. 7.
    Loh K, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20:648-58.CrossRefPubMedGoogle Scholar
  8. 8.
    Forssell-Aronson E, Bernhardt P, Wangberg B, Kolby L, Nilsson O, Ahlman H. Aspects of radionuclide therapy in malignant pheochromocytomas. Ann N Y Acad Sci 2006;1073:498-504.CrossRefGoogle Scholar
  9. 9.
    Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12-7.CrossRefPubMedGoogle Scholar
  10. 10.
    Sisson JC, Shapiro B, Beierwaltes WH, Glowniak JV, Nakajo M, Mangner TJ, et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 1984;25:197-206.PubMedGoogle Scholar
  11. 11.
    Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, et al. Treatment of metastatic carcinoid tumors, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-meta-iodobenzylguanidine (131I-mIBG). Clin Endocrinol (Oxf) 2001;55:47-60.CrossRefGoogle Scholar
  12. 12.
    Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight GS Jr, et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003;134:956-62.CrossRefPubMedGoogle Scholar
  13. 13.
    Rose B, Matthay KK, Price D, Huberty J, Klencke B, Norton JA, et al. High-dose 131I-Metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 2003;98:239-48.CrossRefPubMedGoogle Scholar
  14. 14.
    Blake GM, Lewington VJ, Fleming JS, Zivanovic MA, Ackery DM. Modification by nifedipine of 131I-meta-iodo benzylguanidine kinetics in malignant phaeochromocytoma. Eur J Nucl Med 1988;14:345-8.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Gonca Kara Gedik
    • 1
    Email author
  • Cornelis A. Hoefnagel
    • 2
  • Evert Bais
    • 3
  • Renato A. Valdés Olmos
    • 2
  1. 1.Department of Nuclear Medicine, Faculty of MedicineHacettepe University School of MedicineSıhhiyeTurkey
  2. 2.Department of Nuclear MedicineThe Netherlands Cancer InstituteAmsterdamThe Netherlands
  3. 3.Department of Medical OncologyThe Netherlands Cancer InstituteAmsterdamThe Netherlands

Personalised recommendations